|Slideshows|March 30, 2018

Psychiatry Update: March 2018

Author(s)Natalie Timoshin, Laurie Martin

News from around the web includes reports on physician burnout, the effects of diet on brain inflammation, written exposure therapy for PTSD, Parkland, psychedelics, benzodiazepines, and social media to gauge mental health.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

“Porosity”: Connecting 2 Western Cultural Psychiatric Discourses in Tokyo by Way of Naples

ByVincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych, FRSC

October 29th 2025

Social Determinants of Health and Mental Health: Concepts and Practice of Growing Relevance

ByRenato D. Alarcón, MD, MPH,Dilip V. Jeste, MD

October 16th 2025

The Psychiatric Lens on Extraordinary Experiences: Improving Care Without Misdiagnosis

ByMarina Weiler, PhD,Marieta Pehlivanova, PhD,Philip J. Cozzolino, PhD,J. Kim Penberthy, PhD, ABPP

September 29th 2025

Social Psychiatry and Culturally Relevant Psychotherapy at the APA Annual Meeting

ByLeah Kuntz,Vincenzo Di Nicola, MPhil, MD, PhD, FCAHS, DLFAPA, DFCPA, FACPsych, FRSC

May 28th 2025

Psychiatry and the “Worst Movie Ever Made”

BySamuel R. Weber, MD,David C. Wall, PhD

October 23rd 2024

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Psychiatry Update: March 2018

Newsletter

Related Content

“Porosity”: Connecting 2 Western Cultural Psychiatric Discourses in Tokyo by Way of Naples

Social Determinants of Health and Mental Health: Concepts and Practice of Growing Relevance

The Psychiatric Lens on Extraordinary Experiences: Improving Care Without Misdiagnosis

Social Psychiatry and Culturally Relevant Psychotherapy at the APA Annual Meeting

Psychiatry and the “Worst Movie Ever Made”

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Delay on Cobenfy Alzheimer Disease Psychosis Data Following Phase 3 Study “Irregularities,” New Patients Enrolled

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

Data Presentation on XPro1595 for Alzheimer Disease With Inflammation at CTAD

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State